LONDON, Oct. 12, 2015 /CNW/ - BTG plc (LSE: BTG), a global specialist healthcare company and Mirada Medical Ltd, a medical imaging software company, today announced an important collaboration to develop dosimetry software solutions to optimise radioembolisation therapy with TheraSphere®.
(Logo: http://photos.prnewswire.com/prnh/20150805/255981LOGO )
The companies are working together to provide a more personalised approach to radioembolisation for liver cancer patients, through easy-to-use and bespoke software that helps physicians plan the delivery of a specific radiation dose based on an individual patient's need.
Peter Pattison, BTG General Manager Interventional Oncology, Commercial Operations commented "We are committed to providing patients and healthcare providers with value beyond just our products to improve outcomes for patients and ensure that our therapies are tailored to individual patient needs."
Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented "Our goal is to provide intuitive software that facilitates the clinician's use of multi-modal images to plan radioembolisation therapy with the ultimate aim of leading to better patient outcomes. The collaboration with BTG leverages our image processing expertise and highlights the importance of imaging for planning treatments."
BTG and Mirada are excited to be on this journey together to offer interventional oncology teams more power to personalise and optimise radioembolisation therapy with TheraSphere®, for their patients.
The companies plan to make the software available in 2016.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavours to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: http://www.btg-im.com.
TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumours while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.
In the EU, TheraSphere® is CE Marked for the treatment of hepatic neoplasia. In the US, TheraSphere® is FDA approved under a Humanitarian Device Exemption (HDE) for the treatment of hepatocellular carcinoma (HCC).
For full instructions for use and important safety information, please visit http://www.therasphere.com.
About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada's products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumour board and elsewhere.
The company specialises in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada's advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world's leading healthcare companies.
Mirada Medical was originally spun out of the University of Oxford. The company's technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada's world headquarters in Oxford, England. For more information about Mirada Medical products visit: http://www.mirada-medical.com.
SOURCE BTG and Mirada